Trial Profile
A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled, Multi-Dose Study of Etokimab in Patients with Eosinophilic Asthma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Etokimab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AnaptysBio
- 02 Mar 2020 According to an AnaptysBio media release, the company has decided to postpone the initiation of this study, until results are available from the ECLIPSE trial.
- 08 Nov 2019 According to an AnaptysBio media release, the company has decided to postpone the initiation of its planned Phase 2b etokimab clinical trial in eosinophilic asthma, a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients, until it has the opportunity to analyze the full data set from the ATLAS trial.
- 28 Sep 2018 New trial record